Long-suffering ResApp (ASX:RAP) shareholders are finally starting to see the light of day — the company’s shares have hit their highest point in more than two years.

RAP shares jumped 15 per cent this morning to 31c, on news the company had been selected to join the health and biotech-focused accelerator Startup Creasphere Digital Health Program in Munich.

Not since July 2017, shortly after announcing a redo of an earlier failed trial, have ResApp shares been so attractive.

Startup Creasphere is a 12-week program, starting this month, that will see ResApp work with subject matter experts and mentors from the consumer healthcare business unit of $165 billion French multinational pharma giant Sanofi to explore opportunities to develop consumer health-focused respiratory disease products.

Tony Keating, ResApp CEO, said the news was the cherry on top of a positive few weeks.

“We are very excited to participate in the Startup Creasphere program to build and pilot a consumer health-focused product using our novel respiratory diagnostic algorithms,”he said.

“Collaborating with the consumer healthcare business unit of Sanofi during the program provides ResApp with an outstanding opportunity to explore the direct-to-consumer market alongside global industry leaders.”

The company has seen its share price grow double in the past month, thanks to a string of regulatory approvals for its software, which is designed to help diagnose respiratory diseases.

Read more:

‘We’re quietly confident’: ResApp on European, US approval

Analysts are suddenly bullish on ResApp ahead of a ‘critical’ six months

ResApp trial sends shares up 36pc as rollercoaster ride continues

In more ASX health news

Doggy cancer biotech PharmAust (ASX:PAA) wins awards. The company’s Perth-based synthetic and medicinal chemistry subsidiary Epichem won the WA Industry Export Award 2019 for International Health for its contributions to the global health and biotechnology sector by providing end-to-end support in drug discovery.

Impression Healthcare (ASX:IHL) to treat brain injury. Impression has filed a patent for its experimental medicinal cannabis drug IHL-216A to be used as a neuro-protective agent following concussion to reduce traumatic brain injury.

Althea (ASX:AGH) gains more patients. 2,329 patients have now been prescribed a medicinal cannabis product in Australia made by Althea. 462 patients were added in September, representing the largest number of patients prescribed Althea products in a single month to date.